How to buy Ardelyx stock - 14 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ardelyx stock

Own Ardelyx stock in just a few minutes.

Ardelyx, Inc is a biotechnology business based in the US. Ardelyx shares (ARDX) are listed on the NASDAQ and all prices are listed in US Dollars. Ardelyx employs 129 staff and has a trailing 12-month revenue of around USD$7.6 million.

How to buy shares in Ardelyx

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Ardelyx. Find the stock by name or ticker symbol: ARDX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Ardelyx reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Ardelyx, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Ardelyx. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Ardelyx share price

Use our graph to track the performance of ARDX stocks over time.

Ardelyx shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$4.96 - USD$8.35
50-day moving average USD$6.7438
200-day moving average USD$6.3532
Wall St. target priceUSD$13.86
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.66

Buy Ardelyx shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Ardelyx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ardelyx financials

Revenue TTM USD$7.6 million
Gross profit TTM USD$-57,627,000
Return on assets TTM -24.6%
Return on equity TTM -60.31%
Profit margin 0%
Book value $1.347
Market capitalisation USD$751.9 million

TTM: trailing 12 months

Shorting Ardelyx shares

There are currently 5.7 million Ardelyx shares held short by investors – that's known as Ardelyx's "short interest". This figure is 23.6% up from 4.6 million last month.

There are a few different ways that this level of interest in shorting Ardelyx shares can be evaluated.

Ardelyx's "short interest ratio" (SIR)

Ardelyx's "short interest ratio" (SIR) is the quantity of Ardelyx shares currently shorted divided by the average quantity of Ardelyx shares traded daily (recently around 875859.23664122). Ardelyx's SIR currently stands at 6.55. In other words for every 100,000 Ardelyx shares traded daily on the market, roughly 6550 shares are currently held short.

However Ardelyx's short interest can also be evaluated against the total number of Ardelyx shares, or, against the total number of tradable Ardelyx shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ardelyx's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Ardelyx shares in existence, roughly 60 shares are currently held short) or 0.07% of the tradable shares (for every 100,000 tradable Ardelyx shares, roughly 70 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Ardelyx.

Find out more about how you can short Ardelyx stock.

Ardelyx share dividends

We're not expecting Ardelyx to pay a dividend over the next 12 months.

Ardelyx share price volatility

Over the last 12 months, Ardelyx's shares have ranged in value from as little as $4.96 up to $8.35. A popular way to gauge a stock's volatility is its "beta".

ARDX.US volatility(beta: 1.95)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ardelyx's is 1.947. This would suggest that Ardelyx's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Ardelyx overview

Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site